HemaBites

HemaBites showcase hematology news and short commentaries on recent high-impact articles published in international journals. This blog will keep you up to date with the latest developments and discoveries in the field of hematology.

Monday, July 16, 2018

Increased risk of lymphoma in JAK kinase inhibitor patients with myelofibrosis.
Increased risk of lymphoma in JAK kinase inhibitor patients with myelofibrosis.

Jan Cools​
VIB Center for Cancer Biology, Leuven
KU Leuven Center for Human Genetics, Leuven, Belgium

Cover june2018- social media.pngAn European study warns that JAK kinase inhibitor treatment may increase the risk of lymphoma 15-fold in patients with myelofibrosis. The authors assessed two cohorts of 626 and 929 patients with myeloproliferative neoplasms (MPN), including myelofibrosis patients who were receiving treatment with JAK kinase inhibitors (ruxolitinib or fedratinib). The incidence of B-cell lymphoma was >5% in patients treated with JAK inhibitors and <0.5% in patients who did not receive JAK inhibitors. The lymphomas were of aggressive B-cell type, extra-nodal or leukemic with h​igh MYC expression in the absence of MPN-associated mutati​ons. Lymphomas occurring during JAK kinase inhibitor treatment were preceded by a pre-existing B-cell clone in the 3 patients who could be tested, and thus detection of such pre-existing B-cell clone at start of JAK kinase inhibitor treatment may identify individuals at risk.
Reference
Edit Porpaczy, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood 2018 (https://doi.org/10.1182/blood-2017-10-810739)